Explore Sobi's Invitation to the Aspaveli® Phase 3 VALIANT Data Call
Investors, analysts, and media representatives are cordially invited to join a conference call that will present the findings of the phase 3 VALIANT trial related to Aspaveli®. This call is a great opportunity for stakeholders to hear updates straight from the management of Sobi and a key expert in nephrology, Professor Fadi Fakhouri.
Details of the Conference Call
The conference call is set to occur soon and will be informative. It is scheduled for Tuesday at various times to accommodate different time zones: 12:00 CET, 11:00 GMT, and 07:00 EDT. During this call, you'll receive valuable insights about the trial results from Sobi's team and participate in a Q&A session that encourages community engagement.
How to Access the Presentation
Listeners can access the live presentation through the Sobi website. Slides and other relevant materials will be made available ahead of the call, ensuring all attendees can fully benefit from the information being shared. Make sure to mark your calendars!
Dial-In Information for Participants
To participate, use the following dial-in numbers from different regions:
- Sweden: +46 8 5051 0031
- United Kingdom: +44 207 107 06 13
- United States: +1 631 570 56 13
For detailed numbers from other countries, you can refer to the appropriate resources.
About Sobi
Sobi® is an international biopharmaceutical company dedicated to transforming the lives of patients with rare and debilitating diseases. With a workforce comprising approximately 1,800 individuals across multiple continents, Sobi is committed to delivering innovative therapies in haematology, immunology, and specialty care. The company's revenue reached an impressive SEK 22.1 billion in the past year, reflecting its strong market presence. Sobi's stock (STO: SOBI) is traded on Nasdaq Stockholm, positioning it as a key player in the pharmaceuticals industry.
Innovative Therapies and Global Reach
The firm’s focus on rare diseases shines through its continuous efforts to provide reliable access to advanced therapies. Sobi understands the unique challenges faced by individuals suffering from these conditions and strives to meet their needs with groundbreaking medical solutions.
Participate and Stay Informed
This conference call represents a pivotal moment for stakeholders to engage directly with Sobi’s leadership. It serves not only as a platform to disseminate crucial data but also as a discussion venue fostering dialogue and feedback. If you have an interest in watching the presentation or learning more about Sobi's offerings, be sure to check their website for updates and access information.
Stay Connected with Sobi
For continuous updates on Sobi’s developments, investors and interested parties can connect through various platforms, including social media channels and professional networks. Staying engaged is key to understanding Sobi's direction and advancements.
Frequently Asked Questions
What is the purpose of the Sobi conference call?
The conference call aims to present the phase 3 VALIANT trial results related to Aspaveli® and engage stakeholders through an informative Q&A session.
Who will be presenting during the call?
The presentation will feature insights from Sobi's management team and Professor Fadi Fakhouri, an expert in nephrology.
How can I access the presentation materials?
Presentation materials will be available on the Sobi website prior to the call for all registered participants.
What are the dial-in numbers for the call?
Participants can use the following numbers: Sweden: +46 8 5051 0031, UK: +44 207 107 06 13, US: +1 631 570 56 13.
How can I find more information about Sobi?
More information about Sobi can be found on their official website and their social media profiles.
